Ato pill
Searched over 200M research papers for "ato pill"
Summary
4 papers analyzed
These studies suggest that a single-pill therapy combining amlodipine and atorvastatin is more effective in managing cardiovascular health and improving vascular function in hypertensive patients compared to using either drug alone.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
ATO Pill: Efficacy and Applications in Cardiovascular and Cancer Treatments
Amlodipine/Atorvastatin Single-Pill Therapy for Cardiovascular Risk Reduction
Blood Pressure and Lipid Control
The combination of amlodipine and atorvastatin (AML/ATO) in a single-pill therapy has shown significant benefits in managing cardiovascular (CV) risk factors. A study investigated the efficacy of AML/ATO combined with therapeutic lifestyle changes (TLC) compared to amlodipine (AML) alone with TLC. The results demonstrated that 67.8% of participants receiving AML/ATO achieved both blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) goals, compared to only 9.6% in the AML group. This indicates that the single-pill therapy is substantially more effective in controlling both BP and lipid levels.
Vascular Function Improvement
Further research compared the impact of AML/ATO versus AML alone on vascular function in hypertensive patients. The study found that while both treatments improved brachial flow-mediated dilation (FMD), the combination therapy had a significantly greater effect. Additionally, AML/ATO led to more substantial reductions in triglycerides, cholesterol, and LDL levels after 24 weeks. This suggests that AML/ATO not only helps in achieving BP and lipid targets but also enhances overall vascular health more effectively than AML alone.
Oral Arsenic Trioxide in Cancer Treatment
Acute Promyelocytic Leukemia (APL)
Oral arsenic trioxide (ATO) has emerged as a promising treatment for acute promyelocytic leukemia (APL). Historically, arsenic compounds were used in medicine, but their use declined until the redevelopment of oral ATO in Hong Kong in 2000. Clinical experience with over 200 patients has shown that oral ATO has comparable efficacy to intravenous formulations, with a slightly better safety profile, lower operational costs, and improved patient convenience. This makes oral ATO a viable option for APL treatment, warranting further development and systematic study through well-designed clinical trials.
Relapsed and Refractory Multiple Myeloma
The efficacy of ATO in treating relapsed and refractory multiple myeloma has also been explored. A systematic review of 16 studies revealed that ATO, either as a monotherapy or in combination with other agents, showed partial response rates between 0% and 17% and overall response rates of up to 30%. However, the studies had methodological flaws, and the response rates varied widely. Despite these limitations, the findings suggest potential benefits of ATO in multiple myeloma, though further randomized controlled trials are necessary to confirm its efficacy and establish its role in clinical practice.
Conclusion
The combination of amlodipine and atorvastatin in a single-pill therapy offers significant advantages in managing cardiovascular risk factors, improving both BP and lipid control, and enhancing vascular function. Meanwhile, oral arsenic trioxide shows promise in treating acute promyelocytic leukemia and relapsed multiple myeloma, though further research is needed to validate its efficacy and optimize its use in clinical settings.
Sources and full results
Most relevant research papers on this topic
